Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
- ON THE MOVE
January 22, 2001
- Sankyo, Mochida Tie Up with Riken
January 15, 2001
- Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
- Asahi Chemical Invests US$9 Mil in Circe Biomedical
January 15, 2001
- Sumitomo Ties Up With Gene Logic
January 15, 2001
- Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
- SBS Transfers Tagamet to Sumitomo
January 15, 2001
- NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
- SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
- New Health Ministry's Budget Totals \18 Trillion, +4.5% Over FY2000
January 15, 2001
- Fukujin Becomes Hokuho Iyaku's Major Shareholder
January 15, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…